Schizophrenia is one of the most expensive illnesses. Antipsychotics are an essential component of the acute and preventative treatment of this illness, and long-term treatment is necessary to decrease the risk of psychotic relapse. The efficacy and tolerability of flupentixol was evaluated in a post-marketing surveillance study (PMS) in schizophrenic patients receiving long-term treatment in routine clinical practice. Psychiatrists in office practice treated patients for approximately 10 weeks, with a subsequent follow-up period of up to 18 months. We here report on the follow-up period in 128 patients. The benefit for schizophrenic patients increased with the treatment duration of flupentixol as documented by the Clinical Global Impression (CGI). Subjective quality of life improved during the first study period, and this remained stable in the follow-up period. No increase in body weight was observed during the study. The relapse rate was much lower than in other studies. Anticholinergic medication was necessary for 22.7% of the patients at any time. More than 70% of the psychiatrists involved evaluated the treatment as very good or good. The results of this study suggest that flupentixol is a potent and safe antipsychotic for the long-term treatment of schizophrenia in routine clinical practice.
Adams CE Fenton MK Quraishi S David AS (2001) Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry179: 290–299.
2.
Andlin-Sobocki P Rossler W (2005) Cost of psychotic disorders in Europe". Eur J Neurol12 (Suppl. 1): 74–77.
3.
Bozikas VP Papakosta M Niopas I Karavatos A Mirtsou-Fidani V (2004) Smoking impact on CYP1A2 activity in a group of patients with schizophrenia". Eur Neuropsychopharmacol14: 39–44.
4.
Ciompi L (1989) The dynamics of complex biological psychosocial systems. Four fundamental psycho-biological mediators in the long-term evolution of schizophrenia". Br J Psychiatry Suppl5: 15–21.
5.
Clark RE Bartels SJ Mellman TA Peacock WJ (2002) Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy". Schizophr Bull28: 75–84.
6.
Classen W Laux G (1988) Sensorimotor and cognitive performance of schizophrenic inpatients treated with haloperidol, flupenthixol, or clozapine". Pharmacopsychiatry21: 295–297.
7.
Csernansky JG Mahmoud R Brenner R (2002) A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia". N Engl J Med346: 16–22.
8.
Davis JM Chen N Glick ID (2003) A meta-analysis of the efficacy of second-generation antipsychotics". Arch Gen Psychiatry60: 553–564.
9.
Dolder CR Lacro JP Dunn LB Jeste DV (2002) Antipsychotic medication adherence: is there a difference between typical and atypical agents. Am J Psychiatry159: 103–108.
10.
Gartenmaier A Gaese F Soyka M (1998) "Effizienz von Flupentixol bei schizophrenen Erkrankungen". In: T Glaser M Soyka (eds), Flupentixol.Darmstadt: Steinkopff Verlag; pp. 35–66.
11.
Gattaz WF Diehl A Geuppert MS Hubrich P Schmitt A Linde I (2004) Olanzapine versus flupenthixol in the treatment of inpatients with schizophrenia: a randomized double-blind trial". Pharmacopsychiatry37: 279–285.
12.
Gerlach J (1995) Depot neuroleptics in relapse prevention: advantages and disadvantages". Int Clin Psychopharmacol9 (Suppl 5): 17–20.
13.
Gruber AJ Cole JO (1991) Antidepressant effects of flupenthixol". Pharmacotherapy11: 450–459.
14.
Helmchen H (2003) [Psychiatrists and the pharmaceutical industry]". Nervenarzt74: 955–964.
15.
Heres S Davis J Maino K Jetzinger E Kissling W Leucht S (2006) Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics". Am J Psychiatry163: 185–194.
16.
Hertling I Philipp M Dvorak A Glaser T Mast O Beneke M (2003) Flupenthixol versus risperidone: subjective quality of life as an important factor for compliance in chronic schizophrenic patients". Neuropsychobiology47: 37–46.
17.
Ito C Kubota Y Sato M (1999) A prospective survey on drug choice for prescriptions for admitted patients with schizophrenia". Psychiatry Clin.Neurosci53 (Suppl): S35–S40.
18.
Jablensky A (1995) Schizophrenia: recent epidemiologic issues". Epidemiol Rev17: 10–20.
19.
Jones PB Barnes TR Davies L Dunn G Lloyd H Hayhurst KP (2006) Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)". Arch Gen Psychiatry63: 1079–1087.
20.
Keks NA Altson K Hope J Krapivensky N Culhane C Tanaghow A (1999) Use of antipsychosis and adjunctive medications by an inner urban community psychiatric service". Aust N Z J Psychiatry33: 896–901.
21.
Kuhn KU Quednow BB Landen H Riedel M Thiel M (2004b) [Quality of life and therapeutic result in outpatients with schizophrenia under flupenthixol treatment]". Fortschr Neurol Psychiatr72: 397–403.
22.
Leucht S Barnes TR Kissling W Engel RR Correll C Kane JM (2003) Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials". Am J Psychiatry160: 1209–1222.
23.
Lieberman JA Stroup TS McEvoy JP Swartz MS Rosenheck RA Perkins DO (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia". N Engl J Med353: 1209–1223.
24.
Lieberman JA Tollefson G Tohen M Green AI Gur RE Kahn R (2003) Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol". Am J Psychiatry160: 1396–1404.
25.
Lohse A Lorenzen B Müller-Oerlinghausen, b (2004) "Verordnung von Psychopharmaka." In: Schwabe, W, Pfaffrath, A, (eds), Arzneiverordnungsreport. Heidelberg: Springer; 2005.
26.
Messer T Gaxiola D Schmauss M (2006) "Educational level, employment situation and housing situation of psychiatric in-patients on admission." Psychiatr Prax 1.
27.
Messer T Glaser T Schmauss M (2003) Therapeutischer stellenwert von flupentixol und flupentixoldecanoat.Psychopharmakotherapie 4: 141–150.
28.
Muller P Nerenz H Schaefer E (2002) [The risk of rehospitalisation during therapy with atypical and typical neuroleptics-a contribution to differential indication]". Psychiatr Prax29: 388–391.
29.
Naber D Moritz S Lambert M Pajonk FG Holzbach R Mass R (2001) Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs". Schizophr Res50: 79–88.
30.
Oehl M Hummer M Fleischhacker WW (2000) Compliance with antipsychotic treatment". Acta Psychiatr Scand Suppl407: 83–86.
31.
Pach J Finkbeiner T Glaser T Haug J Osterheider M Tegeler J (1998) [Positive and negative symptoms in chronic schizophrenic patients under maintenance therapy with flupenthixol decanoate for a twelve month perioid]". Fortschr Neurol Psychiatr66: 442–449.
32.
Philipp M Lesch OM Walter H Patras L Kurtz G Schmauss M (2002) Wirksamkeit von Flupentixol vs. Risperidon auf die Negativsymptomatik schizophrener Patienten - Ergebnisse einer multizentrischen doppelblinden Non-Inferioritätsstudie.Psychopharmakotherapie 2: 67–74.
33.
Rabinowitz J Lichtenberg P Kaplan Z Mark M Nahon D Davidson M (2001) Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics". Am J Psychiatry158: 266–269.
34.
Ruhrmann S Kissling W Lesch OM Schmauss M Seemann U Philipp M (2007) Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms". Prog Neuropsychopharmacol Biol Psychiatry31: 1012–1022.
35.
Sanger TM Lieberman JA Tohen M Grundy S Beasley C Tollefson GD (1999) Olanzapine versus haloperidol treatment in first-episode psychosis". Am J Psychiatry156: 79–87.
36.
Skogh E Bengtsson F Nordin C (1999) Could discontinuing smoking be hazardous for patients administered clozapine medication? A case report". Ther Drug Monit21: 580–582.
37.
Suzuki T Uchida H Tanaka KF Nomura K Takano H Tanabe A (2004) Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia". Int J Neuropsychopharmacol7: 133–142.
38.
Tapp A Wood AE Secrest L Erdmann J Cubberley L Kilzieh N (2003) Combination antipsychotic therapy in clinical practice". Psychiatr Serv54: 55–59.
39.
Vogel M Kohnlein O Schmauss M Messer T (2004) [Drug monitoring of antipsychotics and antidepressants during acute admission in a psychiatric state hospital in Germany]". Psychiatr Prax31 (Suppl 1): S173–S174.
40.
Walburn J Gray R Gournay K Quraishi S David AS (2001) Systematic review of patient and nurse attitudes to depot antipsychotic medication". Br J Psychiatry179: 300–307.
41.
Watt DC Katz K Shepherd M (1983) The natural history of schizophrenia: a 5-year prospective follow-up of a representative sample of schizophrenics by means of a standardized clinical and social assessment". Psychol Med13: 663–670.
42.
Wittchen HU Jacobi F (2005) Size and burden of mental disorders in Europe–a critical review and appraisal of 27 studies". Eur Neuropsychopharmacol15: 357–376.
